On February 10, 2022 LinKinVax, a clinical-stage biotechnology company, reported completion of a €4.350 million seed capital funding round (Press release, LinKinVax, FEB 10, 2022, View Source [SID1234648589]). It was led by LinKinVax’s core shareholders and business angels and will enable LinKinVax to accelerate the clinical development of its innovative protein-based vaccine platform, which can be tweaked to changes and mutations in target pathogens.
LinKinVax has already risen to prominence in the French sector, with Bpifrance granting it €31 million under a Covid-related PIA PSCP program and Government "Plan Relance", in May 2021.
LinKinVax’s innovative technology directly targets dendritic cells ("DC"), which play a crucial role in the immune system, stimulating and regulating immune responses. It is predicated on work by the U955 research team at the Vaccine Research Institute/Inserm (VRI) in which Inserm, University of Paris Est Créteil (UPEC), and the Mondor Institute of Biomedical Research (IMRB) participate. Thanks to the potential of its technology platform and the advances in its portfolio, LinKinVax aims to make a decisive contribution to the global public health challenges of infectious diseases and cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
André-Jacques Auberton-Hervé, Chairman co-founder and CEO of LinKinVax commented:
"We are thrilled that our breakthrough vaccine technology has generated so much interest among new investors, and with the renewed trust our longstanding partners, we can push ahead confidently with the next stages of our ambitious clinical program. Our objective is to provide effective vaccines as rapidly as possible to help address the public health challenges linked to the various pathogens we are targeting—HIV, SarsCov2, HPV, papillomavirus-related cancers, chlamydia."
The investors who contributed to the round are: André-Jacques Auberton-Hervé (co-founder and CEO of LinKinVax), Jean-Paul Kress (CEO of Morphosys), Geoffrey Duyk (US biotechnology entrepreneur and investor), Giorgio Anania, Rémi Gaston-Dreyfus and Alain Tingaud (recognized entrepreneurs in the high-tech sector).